|Articles|October 24, 2017

PAREXEL and Microsoft Form Alliance Aimed at Accelerating the Pace of Drug Development

PAREXEL International Corp. and Microsoft Corp. have announced a technology development alliance that plans to help the industry accelerate drug development and provide faster therapies to patients. By combing each companies' expertise and capabilities, this new collbaoration will drive innovation across the life sciences industry.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Trending on Applied Clinical Trials Online

PAREXEL and Microsoft Form Alliance Aimed at Accelerating the Pace of Drug Development

Related Content

Two New Partnerships Aim to Expand Patient Access to Clinical Trials Through Community-Based Research

Where Capability Gaps Hide When Scientific Intent Doesn't Translate Into Operations

ACT Brief: Product Development Assumptions, Portfolio-Level Recruitment Infrastructure, and Risk-Based Quality Integration

From Study-by-Study to Portfolio Recruitment: Q&A with Gaynor Anders, Trialbee

Why Execution Strategy Begins at the Business Decision, Not Study Startup

Trending on Applied Clinical Trials Online

Two New Partnerships Aim to Expand Patient Access to Clinical Trials Through Community-Based Research

ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN

From Study-by-Study to Portfolio Recruitment: Q&A with Gaynor Anders, Trialbee

ACT Brief: Sponsor Accountability in Outsourcing, Biomarker Strategy in Precision Oncology, and Novel Sciatica Therapy

Precision Oncology Trials Need to Reflect the Complexity of Cancer Biology